Skip to main content
letter
. 2024 Aug 7;19:1813–1818. doi: 10.2147/COPD.S468887

Figure 1.

Figure 1

Rate reductions of asthma exacerbations after benralizumab initiation across healthcare settings in the (A) overall sample, (B) ≥1 COPD exacerbation cohort, (C) ≥2 COPD exacerbations cohort, and (D) eosinophil subgroups of the ≥1 COPD exacerbation cohort.

Abbreviations: COPD, chronic obstructive pulmonary disease; ED, emergency department.